A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer (LA/mBC), following on or after completing adjuvant endocrine therapy in routine clinical practice in China.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie oporności na leczenie hormonalne, z mutacją PIK3CA, rakiem piersi z dodatnim receptorem hormonalnym i ujemnym HER2, po nawrocie
- •Pierwsze zastosowanie leku inavolisib
- •Potwierdzona mutacja PIK3CA zatwierdzonym testem
✗ Disqualifies
- •Brak wskazania do leczenia inavolisibem według ulotki leku
- •Leczenie poza standardem opieki dla tego rozpoznania
- •Inne okoliczności utrudniające udział lub obserwację pacjenta
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
The First Affiliated Hospital of Xiamen University
Xiamen, China
Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Hospital of Traditional Chinese Medicine)
Lanzhou, China
The First Hospital of Jilin University
Changchun, China
Wenzhou Medical University Affiliated Second Hospital
Wenzhou, China
Peking University First Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
Sun Yat-sen Memorial Hospital
Guangzhou, China
Zhujiang Hospital, Southern Medical University
Guangzhou, China
Guangdong Provincial Traditional Chinese Medicine Hospital
Guangzhou, China
Guizhou Provincial People's Hospital
Guiyang, China
Hainan Provincial Peoples Hospital
Haikou, China
Harbin Medical University Cancer Hospital
Harbin, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Shandong Provincial Hospital
Jinan, China
Luoyang Central Hospital
Luoyang, China
Jiangxi Cancer Hospital
Nanchang, China
Jiangsu Province Hospital
Nanjing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Zhongshan Hospital Fudan University
Shanghai, China
Liaoning cancer Hospital & Institute
Shenyang, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
Taizhou Hospital of Zhejiang Province
Taizhou, China
Weifang People's Hospital
Weifang, China
Hubei Cancer Hospital
Wuhan, China
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, China
Subei People's Hospital of Jiangsu province
Yangzhou, China
Henan Cancer Hospital
Zhengzhou, China
Trial contact
Reference Study ID Number: ML46361 https://forpatients.roche.com/ No attachments to email below.
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.